Stocks Health care DSGN
NASDAQ · Health careDesign Therapeutics, Inc. (DSGN)
It posted a net loss of $74.1M. In fiscal 2025 capital spending exceeded operating cash flow by $54.6M. At September 30, 2026 it held $15.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Design Therapeutics, Inc.
- Net worth
- Design Therapeutics, Inc. has a market value (market cap) of $675.9M at the latest share price, and shareholders' equity of $202.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $69.8M.
- Cash flow
- In fiscal 2025 operations used $54.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Design Therapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Design Therapeutics, Inc. does
Design Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker DSGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$69.8M | -$1.22 | -$54.6M |
| 2024 | $0 | -$49.6M | -$0.88 | -$43.4M |
| 2023 | n/a | -$66.9M | -$1.19 | -$58.8M |
| 2022 | n/a | -$63.3M | -$1.14 | -$52.2M |
| 2021 | n/a | -$35.5M | -$0.77 | -$30.9M |
| 2021 | $226K | -$8.3M | -$0.52 | -$8.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Design Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026
- November 4, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026
- August 3, 2026
- June 11, 2026
- June 9, 2026Passive stake (5% or more) SCHEDULE 13G
- May 18, 2026Other event 8-K
Insider trades
What the people running Design Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns DSGN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Simeon George13D, may seek influence with 3 related filers | 10.7% | March 11, 2026 |
| Sirenia Capital Management LP13G, passive with 1 related filers | 9.5% | August 14, 2026 |
| Light Irrevocable Trust #1 dated April 22, 201913G, passive with 1 related filers | 6.9% | February 7, 2025 |
| Star Irrevocable Trust #1 dated April 22, 201913G, passive with 1 related filers | 6.9% | February 7, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 137 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| SR One Capital Management, LP | 6,526,476 | 0 |
| Logos Global Management LP | 3,000,000 | +1,050,000 |
| Baker Bros. Advisors LP | 2,678,430 | +92,452 |
| Driehaus Capital Management LLC | 2,661,115 | +916,128 |
| BlackRock, Inc. | 2,660,024 | +526,260 |
| Point72 Asset Management, L.P. | 2,366,453 | -356,301 |
| Trails Edge Capital Partners, LP | 2,001,282 | +1,149,269 |
| Frazier Life Sciences Management, L.P. | 1,809,854 | new |
| Vivo Capital, LLC | 1,612,903 | 0 |
| Vanguard Capital Management LLC | 1,571,022 | +221,172 |
| Caption Management, LLC | 1,118,098 | +1,031,390 |
| Almitas Capital LLC | 1,026,893 | -503,442 |
| Geode Capital Management, LLC | 958,417 | +265,899 |
| Sofinnova Investments, Inc. | 865,135 | new |
| Fmr LLC | 776,462 | -21,949 |
| Morgan Stanley | 765,425 | +108,860 |
| State Street Corp | 736,221 | +76,646 |
| Woodline Partners LP | 700,354 | -261,147 |
| Dimensional Fund Advisors LP | 694,743 | +262,903 |
| Goldman Sachs Group Inc | 656,584 | +151,866 |
Insiders
Questions about DSGN
What does Design Therapeutics, Inc. do?
Design Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as DSGN. Its shares trade on NASDAQ under the ticker DSGN.
What is Design Therapeutics, Inc.'s net worth?
Design Therapeutics, Inc. has a market value (market cap) of $675.9M at the latest share price, and shareholders' equity of $202.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Design Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $74.1M.
When did Design Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Design Therapeutics, Inc.'s next earnings report?
Design Therapeutics, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare DSGN with
Follow DSGN
Get an email when Design Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Design Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.